Ezabenlimab (BI 754091), an Anti-Pd-1 Antibody, in Combination with BI 836880, a VEGF/ Ang2-blocking Nanobody, in Patients (pts) with Advanced Colorectal Cancer (CRC)
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined